dm+d
73572009
Articles
Morphine: informing intrathecal risk assessment
11 August 2022Morphine sulfate products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration
Using opioids for pain relief during pregnancy
10 August 2022Opioid analgesics may be used at any stage of pregnancy at the lowest effective dose for the short-term relief of pain when other analgesics are not effective.
Example medicines to prescribe by brand name in primary care
27 March 2022Prescribe certain medicines by brand to ensure supply of the same product. Examples are grouped by therapeutic area. The list of products is not exhaustive.
Supply and/or administration of Controlled Drugs under a PGD
16 November 2021This article summarises the legal position on the supply and/or administration of controlled drugs under PGDs.
Medicine Compliance Aid Stability
ZomorphEthypharm UK
Ethypharm UK
Zomorph
Capsules m/r - various strengths
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Airtight container
Protect from light
Protect from light. Airtight container. Protect from heat.
22 November 2022
SevredolNapp Pharmaceuticals Ltd
Napp Pharmaceuticals Ltd
Sevredol
Tablets f/c - various strengths
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Airtight container
Protect from light
Airtight container and protect from light.
17 November 2022
Morphgesic SRAdvanz Pharma
Advanz Pharma
Morphgesic SR
Tablets f/c, m/r various strengths
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Airtight container
Protect from light
Airtight container and protect from light.
22 November 2022
MST ContinusNapp Pharmaceuticals Ltd
Napp Pharmaceuticals Ltd
MST Continus
Tablets f/c, m/r various strengths
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Airtight container
Protect from light
Airtight container and protect from light
17 November 2022
MXLNapp Pharmaceuticals Ltd
Napp Pharmaceuticals Ltd
MXL
Capsules m/r - various strengths
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Airtight container
Protect from light
Protect from light. Airtight container.
22 November 2022
Lactation Safety Information
Except for low dose, immediate release oral formulations
Except for low dose, immediate release oral formulations
Other appropriate analgesic
Significant published evidence of use in breastfeeding
Small amounts in breast milk
Used in full-term neonates from birth
Infant monitoring advised, especially in young infants (see summary)
23 September 2020
Low dose, immediate release oral formulations
Low dose, immediate release oral formulations
Significant published evidence of use in breastfeeding
Small amounts in breast milk
Applies to short term, low dose (up to 10mg 4-hourly) oral solutions (e.g. Oramorph) and tablets
Although adverse effects in infant are not likely infant monitoring advised in young infants (see summary)
23 September 2020